Accelerating Medicines Partnership® Program – Common Metabolic Diseases

Overview

Traditionally, common metabolic diseases have been targeted and treated as individual diseases. Their potential shared molecular basis represents an opportunity to treat multiple diseases simultaneously and to provide more effective treatment outcomes.

The Accelerating Medicines Partnership^® (AMP^®) Program Common Metabolic Diseases (AMP CMD) is a precompetitive partnership among government and private-sector partners that harnesses their collective capabilities, scale and resources to therapeutically address multiple metabolic diseases that share common pathogenic drivers and overlapping molecular pathways.

Building on the successful output of AMP Type 2 Diabetes, which collected rich genetic and genomic datasets on over 1.5 million participants with type 2 diabetes and related complications, robust analytic tools, and innovative predictive algorithms, AMP CMD will generate and acquire data to accelerate target discovery across the metabolic disease indications. The AMP CMD Knowledge Portal is the project’s open access knowledge portal will aggregate, analyze and display human genetic and functional genomic data from subjects with type 1 and type 2 diabetes, obesity, cardiovascular, kidney and liver diseases. AMP CMD will apply large scale genetic, genomic, transcriptomic, proteomic, metabolomic approaches to characterize human physiology and pathophysiology at cellular, tissue, organ and whole organism levels.

The AMP CMD initiative will prioritize targets for the metabolic diseases and develop tools to analyze links between them. Like other AMP projects and the program commitment to open access data, information will be made broadly available to the scientific research community with security and ethical protections in place for the subject’s data.

Read more about AMP CMD on the National Institute of Diabetes and Digestive and Kidney Diseases’ website.

Goals

• Expand the AMP CMD Knowledge Portal by generating new and leveraging existing genetic, genomic, and biomarker data.
• Address data gaps in metabolic diseases, including nonalcoholic steatohepatitis, chronic kidney diseases, obesity, atherosclerotic cardiovascular diseases and heart failure, type 2 diabetes/prediabetes, autoimmune diabetes and inflammatory drivers.
• Evolve the AMP CMD Knowledge Portal by developing analytical and visualization tools to support integrative analysis.
• Deliver prioritized targets for these diseases with supporting mechanistic data.

Results and Accomplishments

AMP CMD Knowledge Portal currently houses 368 datasets consisting of 388 traits, representing cohorts from 66 countries.

Media

FNIH Web Announcement (November 18, 2021): The Foundation for the NIH Announces the Release of Four Open-Competition Funding Opportunities

FNIH Press Release (May 26, 2021): The Foundation for the NIH Announces a New Research Initiative to Find Integrated Treatments Across Common Metabolic Diseases